1. Ktisis Cyprus University of Technology

The Core Outcome Measures for Food Allergy (COMFA)

View Statistics Email Alert RSS Feed

Primary Data

Project title
The Core Outcome Measures for Food Allergy (COMFA)
Start date
05-11-2019
Expected Completion
04-11-2022
 
Participant
Project website

Description

Abstract
Food allergy is a major societal challenge in Europe. The disease affects 6%-8% of children under the age of 3 years, and 2-3% of adults and has a quality of life impact similar to other major chronic conditions. Food allergy is a major financial burden, with significant impact on healthcare, education, food and catering industries. New treatments for food allergy are in development. There is however no agreed set of Core Outcomes for evaluating these new treatments. This may prevent the development of effective treatments with marketing approvals from regulatory authorities, for food allergic Europeans.

Core Outcome sets ensure that trial outcomes are relevant to patients, clinicians, healthcare providers and regulators; and they allow trial outcomes to be combined in meta-analysis, so that new findings are capitalized on as soon as possible. The Core Outcome Measures for Food Allergy (COMFA) project is a multidisciplinary network involving all relevant stakeholders aiming to advance food allergy research and innovation by (a) defining the scope and applicability of food allergy Core Outcome sets; (b) developing Core Outcome sets and measurement tools for food allergy; (c) reaching a consensus on terminology and definitions of measurement properties for food allergy Core Outcomes.

This project addresses the Societal Challenges in Health by improving our understanding of health and our ability to reliably monitor health outcomes, and demonstrates new options for healthcare delivery. The outcomes will help improve the quality of clinical trials, and the Action will advance the career of young researchers, strengthening Europe’s leading position in pharmaceutical sciences.
 
Keyword(s)
food allergy
allergic diseases
clinical trials
core outcome sets